Evercore ISI Group downgrades Legend Biotech to In-Line from Outperform, sets price target at $20
Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform, setting a $20 price target, implying 14.3% upside from the Nov 13 close of $17.50. Recent analyst notes on the company have price targets ranging from $25 to $61.
How this was made

The 30-second read
Why it matters
The downgrade reflects concerns about near‑term growth prospects, potentially prompting short sellers.
Market read
Analyst rating changes are a common catalyst for price movement in small‑cap biotech stocks.
What to watch
Potential upcoming clinical trial data could offset the downgrade if results are positive.
Background
Legend Biotech is a U.S.-listed biotech company focused on oncology therapies.
Ticker impact
Evercore ISI Group downgraded Legend Biotech to In-Line from Outperform and set a $20 price target.
likely downward pressure as investors price in the downgrade
Downgrades typically lead to short-term sell pressure, especially for a small‑cap biotech.
Market effects
May weigh on other small‑cap biotech stocks as analysts reassess sector risk.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
Some investors may view the $20 target as a buying opportunity if they believe the downgrade is overly cautious.
Key entities
- analystEvercore ISI Group
Equity research firm issuing the downgrade.


